The specter of generic rivalry has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, triggering questions about the prospects of related pharmaceutical holdings. While initial times saw significant gains, the exclusivity expiration has created the door for cheaper alternatives, potentially reducing profitability and presenting a